Figure 5.
Anti-human CD45RC ABIS-45RC treatment improves aGVHD survival in immune-humanized NSG mice. (A) Total human PBMCs or PBMCs depleted in CD45RChigh or CD45RAhigh or preincubated with anti-CD45RC mAb were transferred in irradiated NSG mice to induce GVHD. Results are expressed in percentage of weight loss (left) and mice survival (right) (2 experiments). **P < .01; ***P < .001. (B) NSG mice transferred with total human PBMCs to induce GVHD were treated with anti-CD45RC (ABIS-45RC) mAb alone or with a suboptimal dose of rapamycin for the indicated time points. Results are expressed in percentage of weight loss (left) and mice survival (right) (4 experiments). *P < .05; **P < .01; ***P < .001. (C) Histogram of the percentage of human CD45+ cells in NSG mice peripheral blood (left) and spleen (right) (days 15, 25, 30, 45, and 60 for peripheral blood and day 25 for spleen). *P < .05.

Anti-human CD45RC ABIS-45RC treatment improves aGVHD survival in immune-humanized NSG mice. (A) Total human PBMCs or PBMCs depleted in CD45RChigh or CD45RAhigh or preincubated with anti-CD45RC mAb were transferred in irradiated NSG mice to induce GVHD. Results are expressed in percentage of weight loss (left) and mice survival (right) (2 experiments). **P < .01; ***P < .001. (B) NSG mice transferred with total human PBMCs to induce GVHD were treated with anti-CD45RC (ABIS-45RC) mAb alone or with a suboptimal dose of rapamycin for the indicated time points. Results are expressed in percentage of weight loss (left) and mice survival (right) (4 experiments). *P < .05; **P < .01; ***P < .001. (C) Histogram of the percentage of human CD45+ cells in NSG mice peripheral blood (left) and spleen (right) (days 15, 25, 30, 45, and 60 for peripheral blood and day 25 for spleen). *P < .05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal